News

The acquisition also includes the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology and LENSAR legacy laser system.

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

The authors noted that while an association between cigarette smoking and TED has been well established, an association between TED and cannabis use has not been determined.

The 9 recipients receive $55,000 in seed money for collaborative projects that target one or more of the foundation’s strategic research goals.

The study findings indicated that lifestyle changes associated with the COVID-19 pandemic were connected to an increase in childhood astigmatisms.

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 of its ongoing phase 1 clinical trial of TH103 in treatment-naïve nAMD patients in the second half of 2025.

Intraoperative floppy iris syndrome is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery

CEO Stephen McLeod, MD, outlines the American Academy of Ophthalmology's commitment to advocating for evidence-based, sustainable, and equitable reforms that prioritize public health and access to quality care.

The bio-interventional platform is for uveoscleral outflow enhancement in open-angle glaucoma patients undergoing combined cataract surgery.

A retrospective study showed that the gender of the ophthalmologist influenced the amount of communication with the patient, and that the pandemic had an impact.

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed them for 18 months.

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

These offerings are designed to streamline workflows for eye care professionals and enhance patient experience.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.

Ambulatory surgical centers are freestanding health care facilities that specialize in providing surgical and diagnostic procedures, not requiring an overnight stay.

The system aids in the orthokeratology lens design process by syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug.

This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately.

The Perimeter B-Series OCT system combines proprietary AI technology with optical coherence tomography, for use during breast-conserving surgeries.

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, a first-in-class mitochondria-targeted investigational therapeutic.